Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06693440Recruiting

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Role: lead

NCT04924413Phase 2Terminated

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Role: lead

NCT05878028Phase 2Recruiting

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Role: lead

All 3 trials loaded